Jackson Scott Thomas — SEC Form 4 filings
SEC reporting owner CIK 1566617. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-25.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-05-01 to 2026-06-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| MACROGENICS INC (MGNX) | Director | 4 | — | — | 12 |
| Mural Oncology plc (MURA) | Director | 4 | — | — | 6 |
| Spero Therapeutics, Inc. (SPRO) | Director | 3 | — | — | 4 |
| GLYCOMIMETICS INC (GLYC) | Director | 1 | — | — | 1 |
Form 4 filings — Jackson Scott Thomas
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-25 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | MACROGENICS INC (MGNX) | Option exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0 · Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Mural Oncology plc (MURA) | Disposition to issuer (D): 8,637 (derivative) · Disposition to issuer (D): 8,462 (derivative) · Disposition to issuer (D): 15,021 (derivative) | EDGAR |
| 2025-06-16 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-06-13 | 4 | Mural Oncology plc (MURA) | Grant/award (A): 8,637 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | MACROGENICS INC (MGNX) | Option exercise (M): 6,500 · Option exercise (M): 6,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0 · Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4/A | Mural Oncology plc (MURA) | Grant/award (A): 8,462 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | Mural Oncology plc (MURA) | Grant/award (A): 8,462 (derivative) @ $3.35 | EDGAR |
| 2024-05-30 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-05-23 | 4 | MACROGENICS INC (MGNX) | Grant/award (A): 6,500 (derivative) @ $0 · Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | MACROGENICS INC (MGNX) | Option exercise (M): 4,500 @ $0 · Option exercise (M): 4,500 (derivative) @ $0 | EDGAR |
| 2024-05-01 | 4 | GLYCOMIMETICS INC (GLYC) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1566617 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →